Document Detail


Delivery outcome in relation to maternal use of some recently introduced antidepressants.
MedLine Citation:
PMID:  18004128     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Little is known concerning possible hazards of maternal use of the recently introduced antidepressant drugs with noradrenergic and varying serotonergic activity (serotonin-noradrenaline reuptake inhibitor [SNRI]/noradrenergic reuptake inhibitor [NRI] drugs). Using the Swedish Medical Birth Registry, we identified 732 women who had used SNRI/NRI drugs in early pregnancy. Maternal characteristics were studied as well as delivery outcome: pregnancy duration, birth weight, neonatal diagnoses, infant deaths, and congenital malformations. Comparisons were made with all deliveries in the population (n = 860,215) after adjustment for identified confounders, and risks were expressed as odds ratios or (when numbers were low) as risk ratios. Women using SNRI/NRI deviated from other women by being older, more often having their first infant, being more extensive smokers, having a higher body mass index, and more often being born within Sweden. These characteristics, like the pattern of concomitant drug use, resembled much those of women using selective serotonin reuptake inhibitor (SSRI) drugs. The rate of preterm births was significantly increased (odds ratio, 1.6; 95% confidence interval, 1.19-2.15), and neonatal symptoms such as respiratory problems, low Apgar score, hypoglycemia, and neonatal convulsions showed a similar pattern as seen after maternal SSRI treatment. We found no increased risk for stillbirths or congenital malformations. Delivery outcome after exposure to SNRI/NRI drugs resembles much what has been described after use of SSRI drugs. No signs of teratogenicity were found.
Authors:
Roland Lennestål; Bengt Källén
Related Documents :
15558298 - Symptoms in relation to chemicals and dampness in newly built dwellings.
10962168 - Factors predicting peri- and neonatal outcome in diabetic pregnancy.
15295368 - The maternal-fetal medicine units cesarean registry: chorioamnionitis at term and its d...
19888918 - Maternal knowledge of infant feeding guidelines and label reading behaviours in a popul...
16354218 - Vitamin d status of mothers and their neonates in kuwait.
3372288 - The effects of prenatal education intervention on unwed prospective adolescent fathers.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical psychopharmacology     Volume:  27     ISSN:  0271-0749     ISO Abbreviation:  J Clin Psychopharmacol     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-16     Completed Date:  2008-02-26     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  8109496     Medline TA:  J Clin Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  607-13     Citation Subset:  IM    
Affiliation:
Department of Clinical Pharmacology, Norrland University Hospital, Umeå, Sweden. rl@pharm.umu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced / epidemiology,  etiology
Abortion, Spontaneous / epidemiology,  etiology
Adrenergic Uptake Inhibitors / adverse effects
Antidepressive Agents / adverse effects*
Birth Weight / drug effects
Cyclohexanols / adverse effects
Databases, Factual / statistics & numerical data
Delivery, Obstetric / statistics & numerical data*
Female
Gestational Age
Humans
Infant Mortality
Infant, Newborn
Mianserin / adverse effects,  analogs & derivatives
Morpholines / adverse effects
Pregnancy
Pregnancy Trimester, First / drug effects
Prenatal Exposure Delayed Effects / chemically induced*,  epidemiology
Registries / statistics & numerical data
Serotonin Uptake Inhibitors / adverse effects
Smoking / adverse effects
Sweden / epidemiology
Chemical
Reg. No./Substance:
0/Adrenergic Uptake Inhibitors; 0/Antidepressive Agents; 0/Cyclohexanols; 0/Morpholines; 0/Serotonin Uptake Inhibitors; 24219-97-4/Mianserin; 61337-67-5/mirtazapine; 93413-69-5/venlafaxine; 98769-81-4/reboxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of single-dose sertraline on the hypothalamus-pituitary-adrenal system, autonomic nervous sys...
Next Document:  Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of tr...